

Joachim Sieper

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7317380/joachim-sieper-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

240
papers

21,293
citations

77
h-index

142
g-index

265
ext. papers

25,751
ext. citations

5.9
avg, IF

6.89
L-index

#	Paper	IF	Citations
240	What amount of structural damage defines sacroiliitis: a CT study.. <i>RMD Open</i> , 2022 , 8,	5.9	1
239	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X2111057975	3.8	1
238	Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis. <i>Rheumatology</i> , 2021 , 60, 5098-5104	3.9	1
237	Diagnostic delay in axial spondyloarthritis - a past or current problem?. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 307-312	5.3	3
236	Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. <i>Arthritis Research and Therapy</i> , 2021 , 23, 106	5.7	9
235	Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 363-369	5.3	1
234	Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. <i>Rheumatology</i> , 2021 , 60, 269-276	3.9	1
233	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021 , 7,	5.9	11
232	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , 2021 , 60, 4778-4789	3.9	13
231	Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	3
230	Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X210987700	3.8	7
229	Spondyloarthritis 2020 , 691-701		1
228	Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. <i>Rheumatology</i> , 2020 , 59, 3798-3806	3.9	21
227	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 88-93	2.4	28
226	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 176-185	2.4	46
225	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2020 , 395, 53-64	4.0	74
224	Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1015-1021	5.3	14

223	Treatment of Axial Spondyloarthritis: What Does the Future Hold?. <i>Current Rheumatology Reports</i> , 2020 , 22, 47	4.9	11
222	The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 210	5.7	9
221	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20972610	3.8	4
220	Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. <i>Joint Bone Spine</i> , 2020 , 87, 69-73	2.9	4
219	IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 1127-1131	2.2	3
218	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1550-1558	2.4	81
217	The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 747-757	8.1	45
216	Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study. <i>Journal of Rheumatology</i> , 2019 , 46, 376-383	4.1	10
215	Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 126	5.7	1
214	Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. <i>Rheumatology</i> , 2019 , 58, 1634-1638	3.9	52
213	Treatment Guidelines for Axial Spondyloarthritis 2019 , 243-258		
212	Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. <i>Rheumatology</i> , 2019 , 58, 1556-1564	3.9	11
211	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. <i>Rheumatology</i> , 2019 , 58, 1649-1654	3.9	15
210	Response to 'Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e55	2.4	
209	Current Unmet Needs in Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2019 , 21, 43	4.9	7
208	Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. <i>RMD Open</i> , 2019 , 5, e000917	5.9	18
207	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. <i>Lancet, The</i> , 2019 , 394, 2108-2117	4.9	104
206	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 872-878	2.4	11

205	Ist eine Hemmung der röntgenologischen Progression bei axialer Spondyloarthritis möglich? <i>Aktuelle Rheumatologie</i> , 2019 , 44, 352-359	0.1	
204	Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis. <i>RMD Open</i> , 2019 , 5, e001108	5.9	29
203	Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 258-270	9.5	153
202	Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. <i>RMD Open</i> , 2019 , 5, e000585	5.9	19
201	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept. <i>Arthritis and Rheumatology</i> , 2019 , 71, 722-728	9.5	13
200	Age- and Sex-dependent Frequency of Fat Metaplasia and Other Structural Changes of the Sacroiliac Joints in Patients without Axial Spondyloarthritis: A Retrospective, Cross-sectional MRI Study. <i>Journal of Rheumatology</i> , 2018 , 45, 915-921	4.1	25
199	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018 , 45, 506-512	4.1	19
198	Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 703-711	3.9	23
197	Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial. <i>Arthritis Research and Therapy</i> , 2018 , 20, 61	5.7	18
196	Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2. <i>RMD Open</i> , 2018 , 4, e000566	5.9	2
195	What low back pain is and why we need to pay attention. <i>Lancet, The</i> , 2018 , 391, 2356-2367	4.0	1251
194	Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1017-1024	2.4	25
193	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
192	What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α or interleukin 17, or both?. <i>Rheumatology</i> , 2018 , 57, 1145-1150	3.9	15
191	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. <i>Arthritis Research and Therapy</i> , 2018 , 20, 166	5.7	6
190	Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1295-1302	2.4	188
189	Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1585-1589	2.4	35
188	Peripheral spondyloarthritis: Concept, diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 357-368	5.3	11

187	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. <i>RMD Open</i> , 2018 , 4, e000825	5.9	24
186	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, placebo-controlled study. <i>Lancet</i> , 2018 , 392, 2451	4.0	161
185	An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus. <i>Arthritis Research and Therapy</i> , 2018 , 20, 191	5.7	9
184	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet</i> , 2018 , 392, 134-144	4.0	42
183	Axial spondyloarthritis. <i>Lancet</i> , 2017 , 390, 73-84	4.0	451
182	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1070-1077 ¹⁶¹	7.4	161
181	Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 571-592	2.4	96
180	Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1502-1508	2.4	88
179	Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC. <i>RMD Open</i> , 2017 , 3, e000366	5.9	17
178	Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis. <i>Journal of Molecular Medicine</i> , 2017 , 95, 779-787	5.5	13
177	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. <i>Rheumatology</i> , 2017 , 56, 1498-1509	3.9	55
176	Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2017 , 69, 1590-1598	4.7	19
175	Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial. <i>BMJ Open</i> , 2017 , 7, e014591	3	9
174	Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time. <i>Rheumatology</i> , 2017 , 56, 1162-1166	3.9	24
173	Associations de patients atteints de spondylarthrite ankylosante Quelles différences entre membres et non-membres ?. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017 , 84, 231-237	0.1	
172	Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. <i>Journal of Rheumatology</i> , 2017 , 44, 599-608	4.1	23
171	Mechanism of New Bone Formation in Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2017 , 19, 55	4.9	30
170	Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. <i>Arthritis Research and Therapy</i> , 2017 , 19, 140	5.7	31

169	Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 746-753	5.3	21
168	Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Arthritis Research and Therapy</i> , 2017 , 19, 240	5.7	23
167	Genetic diagnostic profiling in axial spondyloarthritis: a real world study. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 229-233	2.2	16
166	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1438-43	2.4	123
165	Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. <i>Rheumatology</i> , 2016 , 55, 1946-1953	3.9	11
164	New treatment targets for axial spondyloarthritis. <i>Rheumatology</i> , 2016 , 55, ii38-ii42	3.9	18
163	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF- α Inhibitors for Up to 10 Years. <i>Journal of Rheumatology</i> , 2016 , 43, 2142-2148	4.1	29
162	Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2456-65	9.5	26
161	Ankylosing spondylitis self-help organisations - 'do members differ from non-members?'. <i>Joint Bone Spine</i> , 2016 , 83, 295-300	2.9	3
160	Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus. <i>Journal of International Medical Research</i> , 2016 , 44, 216-30	1.4	9
159	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1958-1963	2.4	259
158	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1034-42	2.4	44
157	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?'. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1262-3	2.4	19
156	Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 404-10	5.3	27
155	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1328-35	2.4	64
154	Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1688-93	9.5	11
153	Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Copenhagen Spondyloarthritis Research Consortium of Canada. <i>Method: Arthritis and Rheumatology</i> , 2016 , 68, 418-29	9.5	32
152	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the German SPondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2114-2118	2.4	71

151	New evidence on the management of spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 282-958.1		77
150	Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 975-983 ^{2,2}		10
149	Reply to the editorial: Can we currently and confidently assess the true burden of illness due to non-radiographic axial spondyloarthritis? by S. van der Linden and M.A. Khan. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 1121	2.2	
148	Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab. <i>Rheumatology</i> , 2015 , 54, 1210-9	3.9	34
147	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1483-7	2.4	71
146	Randomized controlled trial of adalimumab in patients with nonsoriatic peripheral spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 914-23	9.5	51
145	Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. <i>Arthritis and Rheumatology</i> , 2015 , 67, 678-85	9.5	53
144	Classification and diagnosis of axial spondyloarthritis--what is the clinically relevant difference?. <i>Journal of Rheumatology</i> , 2015 , 42, 31-8	4.1	29
143	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1051-7	2.4	106
142	Efficacy of TNF β blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1241-8	2.4	139
141	Axial spondyloarthritis. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15013	51.1	87
140	Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS. <i>Arthritis Research and Therapy</i> , 2015 , 17, 170	5.7	18
139	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2369-75	9.5	22
138	Reply: To PMID 25545240. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2793-4	9.5	3
137	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , 2015 , 373, 2534-48	59.2	619
136	In vivo pre-activation of monocytes in patients with axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 179	5.7	19
135	Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. <i>Rheumatology</i> , 2015 , 54, 257-61	3.9	17
134	The burden of non-radiographic axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 556-562	5.3	84

133	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoesen et al. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e69	2.4	2
132	Management of ankylosing spondylitis/axial spondyloarthritis 2015 , 970-985		
131	Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. <i>Arthritis Research and Therapy</i> , 2014 , 16, R35	5.7	24
130	Clinician Manual on Axial Spondyloarthritis 2014 ,		2
129	Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 667-73	9.5	53
128	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2137-43	2.4	48
127	Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 710-5	2.4	195
126	Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 95-100	2.4	153
125	Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2091-102	9.5	141
124	Erosions and fatty lesions of sacroiliac joints in patients with axial spondyloarthritis: evaluation of different MRI techniques and two scoring methods. <i>Journal of Rheumatology</i> , 2014 , 41, 473-80	4.1	18
123	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 817-23	2.4	195
122	Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. <i>Journal of Rheumatology</i> , 2014 , 41, 2034-40	4.1	23
121	Response to H Zeidler's comments on the INFAST study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e19	2.4	2
120	The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2649-56	9.5	72
119	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
118	I59. New Biologic Treatments for Ankylosing Spondylitis. <i>Rheumatology</i> , 2014 , 53, i13-i13	3.9	
117	Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1746-8	2.4	61
116	Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1745-54	9.5	35

115	Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 377-83 ^{5.3}	46
114	Overview of Axial Spondyloarthritis 2014 , 5-16	2
113	Diagnosis of Axial Spondyloarthritis 2014 , 31-45	2
112	Clinical Manifestations of Axial Spondyloarthritis 2014 , 17-29	
111	Management of Axial Spondyloarthritis 2014 , 59-96	
110	Treatment challenges in axial spondylarthritis and future directions. <i>Current Rheumatology Reports</i> , 2013 , 15, 356	4.9 4
109	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 382, 1705-13	4.0 449
108	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort (GESPIC). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1430-2	2.4 56
107	Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 823-5	2.4 79
106	Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype?. <i>Arthritis and Rheumatism</i> , 2013 , 65, 12-20	77
105	Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 815-22	2.4 347
104	Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1557-65 ^{4.1}	39
103	Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?. <i>Arthritis and Rheumatism</i> , 2013 , 65, 543-51	121
102	In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1522-9	103
101	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SPondyloArthritis international Society (ASAS)-cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1646-53	2.4 102
100	Vertebral erosions associated with spinal inflammation in patients with ankylosing spondylitis identified by magnetic resonance imaging: changes after 2 years of tumor necrosis factor inhibitor therapy. <i>Journal of Rheumatology</i> , 2013 , 40, 1891-6	4.1 11
99	Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 967-73	2.4 96
98	Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1621-7	2.4 81

97	One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 305-6	2.4	38
96	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72 Suppl 2, ii2-34	2.4	96
95	A4.11 Baseline Elevated Serum Levels of Calprotectin as Independent Marker for Radiographic Spinal Progression in Ankylosing Spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A28.1-A28	2.4	
94	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1212-5	2.4	70
93	How important is early therapy in axial spondyloarthritis?. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 635-42	2.4	12
92	Differential synovial Th1 cell reactivity towards Escherichia coli antigens in patients with ankylosing spondylitis and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1573-6	2.4	14
91	How to define remission in ankylosing spondylitis?. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71 Suppl 2, i93-5	2.4	20
90	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 572-4	2.4	162
89	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1616-22	2.4	223
88	Developments in therapies for spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 280-7	8.1	45
87	Classification, diagnosis, and referral of patients with axial spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012 , 38, 477-85	2.4	14
86	Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. <i>Rheumatology International</i> , 2012 , 32, 2801-8	3.6	24
85	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1278-88	2.4	162
84	Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1388-98		287
83	Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 700-6	2.4	65
82	Referral strategies for early diagnosis of axial spondyloarthritis. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 262-8	8.1	92
81	Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful?. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 363-9	5.3	39
80	How to screen for axial spondyloarthritis in primary care?. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 359-62	5.3	14

79	The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1998-2001	2.4	43
78	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 905-8	2.4	302
77	Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. <i>Arthritis Research and Therapy</i> , 2011 , 13, R95	5.7	226
76	Impaired peripheral Th1 CD4+ T cell response to Escherichia coli proteins in patients with Crohn's disease and ankylosing spondylitis. <i>Journal of Clinical Immunology</i> , 2011 , 31, 998-1009	5.7	15
75	Spondyloarthropathies in 2010: new insights into therapy-TNF blockade and beyond. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 78-80	8.1	4
74	Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. <i>Journal of Rheumatology</i> , 2011 , 38, 2452-60	4.1	94
73	Predicting the outcome of ankylosing spondylitis therapy. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 973-81	2.4	124
72	Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 2445-51	4.1	32
71	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. <i>Rheumatology</i> , 2011 , 50, 1690-9	3.9	84
70	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1369-74	2.4	209
69	Relation of HLA-B27, tumor necrosis factor- β promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort. <i>Journal of Rheumatology</i> , 2011 , 38, 2436-41	4.1	14
68	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 249-51	5.1	156
67	Management of ankylosing spondylitis 2011 , 1157-1177.e3		2
66	Current controversies in spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , 2010 , 37, 2617-23	4.1	10
65	Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 823-8	4.1	37
64	Investigation of involved tissue in axial spondyloarthritis--what have we learnt from immunohistochemical studies?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010 , 24, 715-9	5.3	6
63	The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatism</i> , 2009 , 60, 717-27		459
62	HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: potential contribution to local immunopathologic processes in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1635-46		16

61	Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 3257-62		237
60	Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R124	5:7	48
59	Developments in the scientific and clinical understanding of the spondyloarthritides. <i>Arthritis Research and Therapy</i> , 2009 , 11, 208	5:7	34
58	Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2009 , 36, 801-8	4:1	158
57	Can structural damage be prevented in ankylosing spondylitis?. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 335-9	5:3	17
56	Socioeconomic aspects of ankylosing spondylitis 2009 , 73-73		
55	Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. <i>Arthritis Research and Therapy</i> , 2008 , 10, R125	5:7	39
54	The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2008 , 10, R104	5:7	147
53	The safety of celecoxib in ankylosing spondylitis treatment. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 401-4.1	4.1	6
52	Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 578-9		7
51	Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 398-9		1
50	Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics. <i>Current Rheumatology Reports</i> , 2008 , 10, 356-63	4:9	17
49	Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. <i>Arthritis and Rheumatism</i> , 2008 , 58, 649-56		167
48	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1981-91		236
47	Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3402-12		428
46	Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1270-8		86
45	Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1479-84	2:4	125
44	Homologous high-throughput expression and purification of highly conserved E coli proteins. <i>Microbial Cell Factories</i> , 2007 , 6, 18	6:4	9

43	Diagnosing early ankylosing spondylitis. <i>Current Rheumatology Reports</i> , 2007 , 9, 367-74	4.9	17
42	Adalimumab for the treatment of ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 831-8	4	12
41	Ankylosing spondylitis. <i>Lancet, The</i> , 2007 , 369, 1379-1390	40	1210
40	Pathogenesis of Reactive Arthritis 2007 , 181-187		
39	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007 , 34, 510-5	4.1	35
38	Concepts and epidemiology of spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006 , 20, 401-17	5.3	163
37	Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 678-81		124
36	Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. <i>Arthritis and Rheumatism</i> , 2006 , 54, 569-78		371
35	Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1805-13		110
34	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2136-46		630
33	Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2845-51		142
32	Identification of immunodominant CD4+ T cell epitopes in patients with Yersinia-induced reactive arthritis by cytometric cytokine secretion assay. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3583-90		8
31	Early diagnosis of spondyloarthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 536-45		20
30	Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2006 , 8, R143	5.7	125
29	Reactive Spondyloarthritis: Epidemiology, Clinical Features, and Treatment 2006 , 53-64		7
28	Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2006 , 33, 86-90	4.1	63
27	Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. <i>Arthritis Research</i> , 2005 , 7, R439-44		167
26	Diverse effects of infliximab and etanercept on T lymphocytes. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 34, 23-7	5.3	40

25	Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). <i>Arthritis and Rheumatism</i> , 2005 , 52, 582-91		651
24	HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2005 , 52, 892-901		86
23	The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1000-8		361
22	Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthritis. <i>Journal of Immunology</i> , 2004 , 173, 4859-66	5.3	35
21	Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies. <i>Clinical Rheumatology</i> , 2004 , 23, 481-4	3.9	7
20	Disease mechanisms in reactive arthritis. <i>Current Rheumatology Reports</i> , 2004 , 6, 110-6	4.9	19
19	Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. <i>Journal of Rheumatology</i> , 2004 , 31, 531-8	4.1	56
18	Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis. <i>Rheumatic Disease Clinics of North America</i> , 2003 , 29, 595-611	2.4	19
17	Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. <i>Arthritis and Rheumatism</i> , 2002 , 46, 319-27		94
16	Anti-TNF agents for the treatment of spondyloarthropathies. <i>Expert Opinion on Emerging Drugs</i> , 2002 , 7, 235-46	3.7	11
15	Successful short term treatment of severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. <i>Journal of Rheumatology</i> , 2002 , 29, 118-22	4.1	88
14	Pathogenesis of reactive arthritis. <i>Current Rheumatology Reports</i> , 2001 , 3, 412-8	4.9	37
13	Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. <i>Journal of Immunology</i> , 2001 , 167, 4738-46	5.3	111
12	Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1346-52		424
11	Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. <i>Arthritis and Rheumatism</i> , 2000 , 43, 2834-42		64
10	Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. <i>Journal of Immunology</i> , 2000 , 164, 1700-07	5.3	54
9	No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1386-96		128
8	Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2039-44		116

7	Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. <i>Arthritis and Rheumatism</i> , 1998 , 41, 58-67		706
6	Characterization of the synovial T cell response to various recombinant Yersinia antigens in Yersinia enterocolitica-triggered reactive arthritis. Heat-shock protein 60 drives a major immune response. <i>Arthritis and Rheumatism</i> , 1998 , 41, 315-26		81
5	Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1788-97		139
4	Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both?. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1547-54		147
3	The Evolutionarily Conserved Ribosomal Protein L23 and the Cationic Urease ϵ Subunit of Yersinia enterocolitica O:3 Belong to the Immunodominant Antigens in Yersinia-Triggered Reactive Arthritis: Implications for Autoimmunity. <i>Molecular Medicine</i> , 1994 , 1, 44-55	6.2	29
2	Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. <i>Arthritis and Rheumatism</i> , 1994 , 37, 1039-45		256
1	Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases		2